Biofrontera is a biopharmaceutical company specializing in the development and commercialization of dermatological medications and medical cosmetics. By focusing on photodynamic therapy, intensive knowledge of this therapy form has been built up over the years and the company has become an expert in this area. No other company worldwide has made the further development of photodynamic therapy of skin diseases its objective in a comparable manner.
Our most important products include a prescription-only medication to treat non-melanoma skin cancer and its precursors with photodynamic therapy. Our medication has been marketed in the EU since 2012 and in the USA since May 2016. We also market the Belixos® dermal cosmetic series, providing special care for damaged or diseased skin.
Biofrontera is the first German founder-managed pharmaceutical company to receive centralized European and US approval for a medication it has developed itself. Biofrontera currently employs around 130 staff worldwide. The company was founded in 1997 by today's CEO Prof. Hermann Lübbert. Biofrontera AG is listed on the Frankfurt Stock Exchange (Prime Standard), and, since February 2018, on the US NASDAQ Capital Market.